Immunovant
IMVT
147 hedge funds and large institutions have $1.05B invested in Immunovant in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 57 increasing their positions, 45 reducing their positions, and 24 closing their positions.
39% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $10.5M
27% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 45
21% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 24
16% more capital invested
Capital invested by funds: $904M → $1.05B (+$148M)
4% more funds holding
Funds holding: 142 → 147 (+5)
2.2% less ownership
Funds ownership: 44.73% → 42.53% (-2.2%)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$23M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$19.4M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$11.3M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$39.7M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$37.5M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$21.6M |
| 4 |
CAC
Cowen and Company
New York
|
-$19.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$16M |
IMVT Hedge Fund Activity: Q2 2023 in Review
147 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2023, worth a combined $1.05B — up 16% from $904M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new IMVT positions and 24 closed out — a net gain of 5 holders — while 57 added to existing stakes and 45 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $23M. The largest seller was BVF Inc, exiting entirely with an estimated $39.7M sold.
- 147 institutional investors held Immunovant (IMVT) as of Q2 2023, up from 142 in Q1 2023.
- Funds reported $1.05B of Immunovant stock for Q2 2023, up 16% quarter-over-quarter.
- 29 funds opened new Immunovant positions in Q2 2023 and 24 closed out, a net change of +5 holders.
- The largest Immunovant buyer in Q2 2023 was Perceptive Advisors, an estimated $23M added.
- The largest Immunovant seller in Q2 2023 was BVF Inc, an estimated $39.7M sold.
Based on aggregated 13F filings for Q2 2023.